METTL1 inhibitor slowed cancers in mouse models, study reports
A Nature study reported that an experimental METTL1 inhibitor reduced tumor growth and extended survival in several mouse cancer models.
Researchers described STM9005 as a selective inhibitor of the tRNA methyltransferase METTL1 and reported effects across cell models and mice with several cancer types.
The work is preclinical and does not establish a treatment for people.